Abstract:Clinical GeneticsVolume 88, Issue 1 p. 32-33 HOTSPOTS CRISPR screen: a high-throughput approach for cancer genetic research Xiao-Jie Lu, Xiao-Jie Lu [email protected] Department of Gastroenterology, Shanghai East Hospital, Tongji University School of Medicine, Shanghai, ChinaThese authors are co-first authors.Search for more papers by this authorYuan-Yuan Xiang, Yuan-Yuan Xiang Cervical Disease Clinic, Jiangsu Huai'an Maternity and Children Hospital, Huai'an, ChinaThese authors are co-first authors.Search for more papers by this authorXue-Jing Li, Corresponding Author Xue-Jing Li Department of Rehabilitation, The Affiliated Huai'an Hospital of Xuzhou Medical College and The Second People's Hospital of Huai'an, Huai'an, ChinaThese authors are co-first authors.Search for more papers by this author Xiao-Jie Lu, Xiao-Jie Lu [email protected] Department of Gastroenterology, Shanghai East Hospital, Tongji University School of Medicine, Shanghai, ChinaThese authors are co-first authors.Search for more papers by this authorYuan-Yuan Xiang, Yuan-Yuan Xiang Cervical Disease Clinic, Jiangsu Huai'an Maternity and Children Hospital, Huai'an, ChinaThese authors are co-first authors.Search for more papers by this authorXue-Jing Li, Corresponding Author Xue-Jing Li Department of Rehabilitation, The Affiliated Huai'an Hospital of Xuzhou Medical College and The Second People's Hospital of Huai'an, Huai'an, ChinaThese authors are co-first authors.Search for more papers by this author First published: 08 May 2015 https://doi.org/10.1111/cge.12606Citations: 1 Read the full textAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onEmailFacebookTwitterLinkedInRedditWechat No abstract is available for this article. References 1Wang T, Wei JJ, Sabatini DM, Lander ES. Genetic screens in human cells using the CRISPR-Cas9 system. Science 2014: 343 (6166): 80–84. 2Shalem O, Sanjana NE, Hartenian E et al. Genome-scale CRISPR-Cas9 knockout screening in human cells. Science 2014: 343 (6166): 84–87. 3Zalatan JG, Lee ME, Almeida R et al. Engineering complex synthetic transcriptional programs with CRISPR RNA scaffolds. Cell 2015: 160 (1–2): 339–350. 4Konermann S, Brigham MD, Trevino AE et al. Genome-scale transcriptional activation by an engineered CRISPR-Cas9 complex. Nature 2015: 517 (7536): 583–588. 5O'Connell MR, Oakes BL, Sternberg SH et al. Programmable RNA recognition and cleavage by CRISPR/Cas9. Nature 2014: 516 (7530): 263–266. Citing Literature Volume88, Issue1July 2015Pages 32-33 ReferencesRelatedInformation

Table S1 from Epigenetic CRISPR Screens Identify <i>npm1</i> As a Therapeutic Vulnerability in Non–Small Cell Lung Cancer

Table S2 from Epigenetic CRISPR Screens Identify Npm1 As a Therapeutic Vulnerability in Non–Small Cell Lung Cancer

Epigenetic CRISPR Screens Identify Npm1 as a Therapeutic Vulnerability in Non–Small Cell Lung Cancer

Supplementary Table 4 from Proteomic Profiling Identifies Dysregulated Pathways in Small Cell Lung Cancer and Novel Therapeutic Targets Including PARP1

Supplementary Table 2 from Proteomic Profiling Identifies Dysregulated Pathways in Small Cell Lung Cancer and Novel Therapeutic Targets Including PARP1

Supplementary Table 7 from Proteomic Profiling Identifies Dysregulated Pathways in Small Cell Lung Cancer and Novel Therapeutic Targets Including PARP1

Genome-wide CRISPR Screens Reveal a Wnt–FZD5 Signaling Circuit As a Druggable Vulnerability of RNF43-mutant Pancreatic Tumors

Figure S10 from <i>in Vivo</i> Epigenetic CRISPR Screen Identifies <i>asf1a</i> As an Immunotherapeutic Target in &Lt;i>kras</i>-Mutant Lung Adenocarcinoma

Figure S5 from <i>in Vivo</i> Epigenetic CRISPR Screen Identifies <i>asf1a</i> As an Immunotherapeutic Target in &Lt;i>kras</i>-Mutant Lung Adenocarcinoma

Figure S15 from in Vivo Epigenetic CRISPR Screen Identifies Asf1a As an Immunotherapeutic Target in Kras-Mutant Lung Adenocarcinoma

Figure S16 from <i>in Vivo</i> Epigenetic CRISPR Screen Identifies <i>asf1a</i> As an Immunotherapeutic Target in &Lt;i>kras</i>-Mutant Lung Adenocarcinoma

Genetic and Pharmacological Interrogation of Cancer Vulnerability Using a Multiplexed Cell Line Screening Platform

Prioritization of cancer therapeutic targets using CRISPR–Cas9 screens

Supplementary Table S1 from Receptor-interacting Protein Kinase 2 is an Immunotherapy Target in Pancreatic Cancer

Figure S6 from in Vivo Epigenetic CRISPR Screen Identifies Asf1a As an Immunotherapeutic Target in Kras-Mutant Lung Adenocarcinoma

A CRISPR Dropout Screen Identifies Genetic Vulnerabilities and Therapeutic Targets in Acute Myeloid Leukemia

High-resolution characterization of gene function using single-cell CRISPR tiling screen

Table S3 from Paradoxical Activation of Oncogenic Signaling as a Cancer Treatment Strategy

CRISPR Screen: a High‐throughput Approach for Cancer Genetic Research

Figure S14 from <i>in Vivo</i> Epigenetic CRISPR Screen Identifies <i>asf1a</i> As an Immunotherapeutic Target in &Lt;i>kras</i>-Mutant Lung Adenocarcinoma

CRISPR Dependency Screens in Primary Hematopoietic Stem Cells Identify KDM3B as a Genotype Specific Vulnerability in IDH2- and TET2-Mutant Cells

Table S1 from Epigenetic CRISPR Screens Identify &lt;i&gt;npm1&lt;/i&gt; As a Therapeutic Vulnerability in Non–Small Cell Lung Cancer